0M61 Stock Chart & Stats
€1.37
-€0.05(-5.95%)
At close: 4:00 PM EDT
€1.37
-€0.05(-5.95%)
Day’s Range― - ―
52-Week Range€0.54 - €1.60
Previous CloseN/A
Volume0.00
Average Volume (3M)403.00
Market Cap
€42.86M
Enterprise Value€51.03
Total Cash (Recent Filing)€13.45M
Total Debt (Recent Filing)€20.08M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding39,607,853
10 Day Avg. Volume0
30 Day Avg. Volume403
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.02Price Target Upside193.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)€38.87M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginRevenue has reached meaningful scale while maintaining a strong gross margin, indicating that Myomo's device economics retain value as sales expand. Continued top-line growth could provide a foundation for operating leverage if the company can convert gross profit into lower fixed costs and eventual profitability.
Specialized MyoPro ProductMyoPro addresses upper-limb weakness with a specialized wearable medical robotics solution that supports functional movement in daily activities. Its combination of EMG signal detection and powered assistance gives Myomo a focused product platform in assistive technology rather than a generic medical device offering.
Reimbursable Direct-to-Patient ModelThe direct-to-patient model connects device delivery with reimbursement channels that can include commercial insurers and government programs. This structure gives Myomo multiple payment pathways and aligns revenue generation with fitting and delivering a product intended to address significant functional limitations.
Bears Say
Persistent UnprofitabilityMyomo has not yet demonstrated durable operating leverage despite revenue growth and solid gross margins. Persistent operating and net losses can constrain reinvestment, increase reliance on external financing, and make future earnings more sensitive to the pace at which expenses scale relative to device sales.
Negative And Worsening Cash FlowThe business continues to consume cash rather than fund operations internally, and the reported deterioration in free cash flow indicates that cash burn remains a material operating weakness. Sustained negative generation reduces financial flexibility and may require additional funding before growth becomes self-financing.
Higher Leverage And Shrinking EquityRising debt alongside a shrinking equity base has reduced balance-sheet flexibility and increased financing risk while losses persist. Higher leverage can limit the company's ability to absorb operating setbacks, fund expansion internally, or secure future capital on terms that preserve shareholder value.
Myomo News
0M61 FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was €0.54 and its highest was €1.60 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is €42.86M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Nov 11, 2026 which is in 54 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on Aug 05, 2026. The company reported -€0.077 earnings per share for the quarter, beating the consensus estimate of -€0.084 by €0.007.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.07.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 39,607,853 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -€0.077 in its last earnings report, beating expectations of -€0.084. Following the earnings report the stock price went up 32.745%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in DE:0M61
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.02 (193.68% Upside)
€4.02 (193.68% Upside)
Blogger Sentiment
Bullish
DE:0M61 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth €43.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
0M61 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all DE:0M61 earnings summaries0M61 Stock 12 Month Forecast
Average Price Target
€4.02
▲(193.68% Upside)